Two Sigma Advisers LP Purchases 11,700 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Two Sigma Advisers LP lifted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 226,400 shares of the biopharmaceutical company's stock after purchasing an additional 11,700 shares during the period. Two Sigma Advisers LP owned about 0.19% of Cytokinetics worth $10,650,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Jones Financial Companies Lllp grew its holdings in Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics during the fourth quarter worth $29,000. AlphaQuest LLC lifted its holdings in shares of Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,135 shares during the period. J.Safra Asset Management Corp boosted its stake in shares of Cytokinetics by 62.1% in the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 671 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 842 shares during the last quarter.

Cytokinetics Stock Up 0.2%

Shares of NASDAQ CYTK traded up $0.05 during mid-day trading on Monday, reaching $30.54. 1,789,501 shares of the company's stock traded hands, compared to its average volume of 1,620,482. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The business has a 50-day simple moving average of $37.58 and a 200 day simple moving average of $44.41. The stock has a market cap of $3.65 billion, a P/E ratio of -5.68 and a beta of 0.81. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $61.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.77 million. Cytokinetics's revenue for the quarter was up 89.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.33) EPS. On average, analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Insider Activity at Cytokinetics

In other Cytokinetics news, Director Muna Bhanji sold 1,454 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $29.73, for a total transaction of $43,227.42. Following the transaction, the director now directly owns 23,510 shares in the company, valued at approximately $698,952.30. This trade represents a 5.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew Callos sold 3,341 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares of the company's stock, valued at approximately $2,788,059.18. The trade was a 4.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,816 shares of company stock valued at $3,850,385 over the last 90 days. Insiders own 2.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Citigroup dropped their target price on shares of Cytokinetics from $86.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research report on Monday, April 21st. Needham & Company LLC restated a "buy" rating and set a $72.00 target price on shares of Cytokinetics in a research report on Wednesday, May 14th. Barclays decreased their target price on Cytokinetics from $55.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Finally, Royal Bank of Canada dropped their price target on Cytokinetics from $82.00 to $80.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $74.73.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.